[go: up one dir, main page]

MX2018012716A - Peptidos bioactivos pegilados y usos de los mismos. - Google Patents

Peptidos bioactivos pegilados y usos de los mismos.

Info

Publication number
MX2018012716A
MX2018012716A MX2018012716A MX2018012716A MX2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A
Authority
MX
Mexico
Prior art keywords
bioactive peptides
subject
modified
positions
peg moiety
Prior art date
Application number
MX2018012716A
Other languages
English (en)
Inventor
G Peri Krishna
Original Assignee
Griffon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffon Pharmaceuticals Inc filed Critical Griffon Pharmaceuticals Inc
Publication of MX2018012716A publication Critical patent/MX2018012716A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente péptidos bioactivos que se modifican en una o más posiciones con una porción de PEG. Un ejemplo de este péptido bioactivo PEGilado es un análogo de GHRH que se modifica en una o más posiciones con una porción PEG. También se describen sales farmacéuticamente aceptables de los mismos y composiciones farmacéuticas que comprenden tales análogos o sales de los mismos, así como métodos, kits y usos de los mismos, por ejemplo para inducir o estimular la secreción de la hormona de crecimiento en un sujeto y para diagnosticar, prevenir o tratar afecciones deficientes de GH en un sujeto.
MX2018012716A 2016-04-19 2017-04-18 Peptidos bioactivos pegilados y usos de los mismos. MX2018012716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2018012716A true MX2018012716A (es) 2019-02-11

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012716A MX2018012716A (es) 2016-04-19 2017-04-18 Peptidos bioactivos pegilados y usos de los mismos.

Country Status (18)

Country Link
US (2) US9988428B2 (es)
EP (1) EP3445778B1 (es)
JP (1) JP7134093B2 (es)
KR (1) KR102520348B1 (es)
CN (1) CN109153712B (es)
AU (1) AU2017254754B2 (es)
BR (1) BR112018070929A2 (es)
CA (1) CA3021231A1 (es)
DK (1) DK3445778T3 (es)
ES (1) ES2824781T3 (es)
HU (1) HUE052802T2 (es)
IL (1) IL262356B2 (es)
MX (1) MX2018012716A (es)
PL (1) PL3445778T3 (es)
PT (1) PT3445778T (es)
RU (1) RU2748576C2 (es)
SG (1) SG11201808880PA (es)
WO (1) WO2017181277A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527190A (ja) 2019-03-29 2022-05-31 ザ ジェネラル ホスピタル コーポレイション 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物
JP7542641B2 (ja) 2020-10-09 2024-08-30 オートリブ ディベロップメント エービー エアバッグ装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
AU662731B2 (en) 1991-04-09 1995-09-14 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
JPH11503454A (ja) 1995-04-14 1999-03-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 成長ホルモン放出因子の類似体
DE69614849T2 (de) 1995-05-26 2002-05-16 Theratechnologies Inc., Montreal Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
EP1204321B1 (en) 1999-07-26 2005-11-09 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
AU9558901A (en) 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
CN1688696A (zh) 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
CA2620638A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
CN101983066B (zh) * 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
RU2011125366A (ru) 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
CA2833434A1 (en) 2011-04-21 2012-10-26 Theratechnologies Inc. Growth hormone releasing factor (grf) analogs and uses thereof
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
WO2017023933A2 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
KR20180135016A (ko) 2018-12-19
EP3445778A1 (en) 2019-02-27
RU2018140501A3 (es) 2020-09-08
US20170296628A1 (en) 2017-10-19
ES2824781T3 (es) 2021-05-13
CN109153712B (zh) 2022-09-16
SG11201808880PA (en) 2018-11-29
IL262356B2 (en) 2023-06-01
US20190209699A1 (en) 2019-07-11
BR112018070929A2 (pt) 2019-02-26
PT3445778T (pt) 2020-10-15
DK3445778T3 (da) 2020-10-12
US9988428B2 (en) 2018-06-05
JP7134093B2 (ja) 2022-09-09
RU2748576C2 (ru) 2021-05-27
PL3445778T3 (pl) 2021-02-22
CN109153712A (zh) 2019-01-04
EP3445778A4 (en) 2019-05-01
AU2017254754B2 (en) 2021-02-04
JP2019516675A (ja) 2019-06-20
EP3445778B1 (en) 2020-07-15
IL262356A (en) 2018-11-29
WO2017181277A1 (en) 2017-10-26
AU2017254754A1 (en) 2018-11-01
RU2018140501A (ru) 2020-05-19
HUE052802T2 (hu) 2021-05-28
CA3021231A1 (en) 2017-10-26
KR102520348B1 (ko) 2023-04-10
US10918730B2 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
ZA201900367B (en) Formulation of a peptide vaccine
CL2018000215A1 (es) Uso de variantes de péptido natriuretico de tipo c para tratar displasia esquelética.
MX2020004969A (es) Composiciones y procedimientos para tratar cancer.
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
PH12018502465A1 (en) Mic-1 compounds and use thereof
EA201990298A1 (ru) Способы и композиции для лечения рака
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
MX2018012716A (es) Peptidos bioactivos pegilados y usos de los mismos.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
DOP2022000097A (es) Agonistas del receptor npy2
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
MX2016011852A (es) Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
AR112785A1 (es) Composición de péptidos asociados a tumores proliferativos e inmunógeno anti-cáncer relacionado para el tratamiento de cánceres de pulmón y otros cánceres
WO2018031730A3 (en) Peptide inhibitors of phosphoglycerate mutase and methods of use
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
EP4427806A3 (en) Composition for controlled ovarian stimulation
RU2018125290A (ru) Фармацевтические композиции и их применение для лечения пигментного ретинита
MX2022003598A (es) Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.